Vaccine Makers Rise Amid Bird Flu Vaccine Hope After First U.S. Death
Vaccine makers rose after the first bird flu death was reported in the U.S.
Novavax up 14%, Moderna up 12%, CureVac up 11%, BioNTech up 5%, Pfizer up 2%.
Moderna is one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, which is spreading rapidly through farms and wild animals in North America.
As of Jan. 6, there have been 66 confirmed human cases of H5N1 bird flu in the U.S. since 2024 and 67 since 2022, according to the Centers for Disease Control and Prevention.
Pfizer and GSK in partnership with CureVac are also developing mRNA vaccines for bird flu.
CureVac, a Germany-based biotech with a market cap of just under $1 billion, rose in Tuesday trading after a 23% gain Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10